Certara is a pharmaceutical company that accelerates medicines with biosimulation software and technology.
Certara is a pharmaceutical company that accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries. Certara's end-to-end platform includes biosimulation, regulatory science, and market access solutions. It integrates its unique portfolio of software and technology-enabled services spanning discovery to post-approval.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 7, 2022 | Post-IPO Secondary | $449M | 1 | Arsenal Capital Partners | — | Detail |
Sep 20, 2021 | Grant | — | 1 | — | — | Detail |
Sep 13, 2021 | Post-IPO Equity | $139.50M | — | — | — | Detail |
Mar 25, 2021 | Post-IPO Equity | $250M | 1 | Mubadala | — | Detail |
Dec 10, 2020 | IPO | $668.26M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Arsenal Capital Partners | Yes | Post-IPO Secondary |
Mubadala | Yes | Post-IPO Equity |
U.S. Food and Drug Administration | — | Grant |
Certara has acquired 8 organizations. Their most recent acquisition was Tripos International on Jan 1, 2008. They acquired Tripos International for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Jan 1, 2008
Tripos International
|
Biotechnology | acquisition | — | Detail |
Mar 13, 2012
Simcyp
|
Health Care | acquisition | — | Detail |
Aug 13, 2013
Great Lakes Drug Development
|
Health Care | acquisition | — | Detail |
Apr 5, 2014
Synchrogenix
|
Biotechnology | acquisition | — | Detail |
Dec 1, 2015
XenologiQ
|
Biotechnology | acquisition | — | Detail |